Chief of Strategic Partnerships
Dana-Farber Cancer Institute
Boston, MA
For revered clinical and translational research that has transformed the treatment of oncogene-driven lung cancers. Dr. Shaw’s groundbreaking work in defining ALK- and ROS1-positive lung cancers and leading the preclinical and clinical development of first and next generation inhibitors have established new standards of care, dramatically improving patient outcomes. Additionally, her research on resistance mechanisms and innovative strategies to overcome resistance have helped guide the development of targeted therapies across numerous other molecularly defined subsets of cancer.
The AACR and Bristol-Myers Squibb established the AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research in 1996 to recognize outstanding achievements in clinical cancer research. The award honors Dr. Joseph H. Burchenal, honorary member and past president of the AACR, and a major figure in clinical cancer research. To learn more, please visit the press release.
View Past Recipients.